Status:
COMPLETED
Cognition in the Study of Tamoxifen and Raloxifene
Lead Sponsor:
Wake Forest University
Collaborating Sponsors:
National Institute on Aging (NIA)
Conditions:
Cognition
Aging
Eligibility:
FEMALE
65+ years
Phase:
PHASE3
Brief Summary
The purpose of this study is to assess the effects of tamoxifen and raloxifene on cognitive aging in selected cognitively-healthy women.
Detailed Description
Recent reports indicate that hormone therapy (HT) may have a protective effect on the aging brain. Although previous studies have examined the effects of HT on age-related cognitive changes, there is ...
Eligibility Criteria
Inclusion
- Women enrolled in STAR trial at a site participating in Co-STAR
- 65 years of age or older
- Have been randomized into STAR but have not started taking the study drug OR enrolled in STAR for a minimum of one year
- Have not been diagnosed with dementia
- Have signed a separate consent document for the Co-STAR Study
- Previous diagnoses of chronic neurologic disease (Parkinson's disease, stroke, epilepsy, multiple sclerosis), history of head injury, depression, alcohol addiction, drug addiction, and other neurologic or psychiatric conditions will be recorded but will not serve as exclusion factors for this study
Exclusion
- Not enrolled in the STAR Trial
- Younger than 65 years of age
- Diagnosed with dementia
Key Trial Info
Start Date :
October 1 2001
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2008
Estimated Enrollment :
1498 Patients enrolled
Trial Details
Trial ID
NCT00687102
Start Date
October 1 2001
End Date
March 1 2008
Last Update
September 12 2018
Active Locations (134)
Enter a location and click search to find clinical trials sorted by distance.
1
CCOP Western Regional
Phoenix, Arizona, United States, 85006
2
Arizona Cancer Center
Tucson, Arizona, United States, 85719
3
Naval Hospital Camp Pendleton
Camp Pendleton, California, United States, 92055
4
City of Hope National Medical Center
Duarte, California, United States, 91010